Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 89BIO in a research note on Saturday, September 27th. HC Wainwright cut shares of 89BIO from a “buy” rating to a “neutral” rating and set a $14.50 price target for the company. Finally, Wolfe Research cut shares of 89BIO from an “outperform” rating to a “peer perform” rating in a research report on Friday, September 19th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and five have issued a Hold rating to the company’s stock. 89BIO Company Profile(Get Free Report)89bio, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases.